Compare Goodyear Tire & Rubber Co (GT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Goodyear Tire & Rubber (GT) trades at $4.56, up 1.56% today but remains under significant pressure with a bearish technical signal. The company reported a net loss of $1.72 billion in 2025, with negative profit margins and declining revenue. Recent news highlights a turnaround strategy focusing on premium tire segments, while cash flow improved slightly to a net inflow of $46 million.

The outlook is challenged by persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include execution of the restructuring plan, competitive pressures, and macroeconomic headwinds affecting tire demand. Institutional sentiment is mixed, with a majority hold rating reflecting caution amid transformation efforts.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.